Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline Looks To Revamp U.S. Operations In Tough Environment

This article was originally published in The Pink Sheet Daily

Executive Summary

U.S. sales fell 13 percent in the third quarter due to generic competition and Avandia.
Advertisement

Related Content

Cervarix, Gardasil Set For FDA Advisory Committee Review
Cervarix, Gardasil Set For FDA Advisory Committee Review
GSK resubmits BLA for Cervarix
GSK resubmits BLA for Cervarix
Can Big Pharma Save Biotech Investors?
Can Big Pharma Save Biotech Investors?
First EU Centralized Switch Goes To Alli, Could Spark More Applications
Amgen Shines In Dark Times, Stays Mum On Bone-Drug Plans
GSK's Oncology Pipeline: Phase III
FDA Starts Process For Regulating Next-generation Vaccine Adjuvants

Topics

Advertisement
UsernamePublicRestriction

Register

PS066918

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel